Vonicog Alfa

Summary

Vonicog Alfa (CHEMBL2107873) is an approved protein; indicated across 2 conditions including von willebrand disease (hereditary or acquired).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• Indications: 2 conditions
• Clinical trials: 4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107873
Name	Vonicog Alfa
Type	Protein
Max phase	4

Also known as: BAX 111, BAX-111, Veyvondi, Von willebrand factor (recombinant), Vonicog alfa, Vonvendi, VONICOG ALFA

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
von Willebrand disease (hereditary or acquired)	4	MONDO:0024574	Orphanet:903

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE3	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05582993	PHASE3	RECRUITING	A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)
NCT07129343	PHASE3	RECRUITING	A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)
NCT02932618	PHASE3	COMPLETED	A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
NCT02973087	PHASE3	COMPLETED	rVWF IN PROPHYLAXIS

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).